[1]
Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA: a cancer journal for clinicians. 2017 Jan:67(1):7-30. doi: 10.3322/caac.21387. Epub 2017 Jan 5
[PubMed PMID: 28055103]
[2]
Kiran RP, Pokala N, Dudrick SJ. Incidence pattern and survival for gallbladder cancer over three decades--an analysis of 10301 patients. Annals of surgical oncology. 2007 Feb:14(2):827-32
[PubMed PMID: 17109082]
[3]
Roa I, Araya JC, Villaseca M, De Aretxabala X, Riedemann P, Endoh K, Roa J. Preneoplastic lesions and gallbladder cancer: an estimate of the period required for progression. Gastroenterology. 1996 Jul:111(1):232-6
[PubMed PMID: 8698204]
[4]
Intrahepatic cholangiocarcinoma: Molecular markers for diagnosis and prognosis., Rahnemai-Azar AA,Weisbrod A,Dillhoff M,Schmidt C,Pawlik TM,, Surgical oncology, 2017 Jun
[PubMed PMID: 28577718]
[5]
Prasad TL, Kumar A, Sikora SS, Saxena R, Kapoor VK. Mirizzi syndrome and gallbladder cancer. Journal of hepato-biliary-pancreatic surgery. 2006:13(4):323-6
[PubMed PMID: 16858544]
[6]
Furlan A, Ferris JV, Hosseinzadeh K, Borhani AA. Gallbladder carcinoma update: multimodality imaging evaluation, staging, and treatment options. AJR. American journal of roentgenology. 2008 Nov:191(5):1440-7. doi: 10.2214/AJR.07.3599. Epub
[PubMed PMID: 18941083]
[7]
Strom BL, Maislin G, West SL, Atkinson B, Herlyn M, Saul S, Rodriguez-Martinez HA, Rios-Dalenz J, Iliopoulos D, Soloway RD. Serum CEA and CA 19-9: potential future diagnostic or screening tests for gallbladder cancer? International journal of cancer. 1990 May 15:45(5):821-4
[PubMed PMID: 2335386]
[8]
Ito H, Ito K, D'Angelica M, Gonen M, Klimstra D, Allen P, DeMatteo RP, Fong Y, Blumgart LH, Jarnagin WR. Accurate staging for gallbladder cancer: implications for surgical therapy and pathological assessment. Annals of surgery. 2011 Aug:254(2):320-5. doi: 10.1097/SLA.0b013e31822238d8. Epub
[PubMed PMID: 21617582]
[9]
Jayaraman S, Jarnagin WR. Management of gallbladder cancer. Gastroenterology clinics of North America. 2010 Jun:39(2):331-42, x. doi: 10.1016/j.gtc.2010.02.006. Epub
[PubMed PMID: 20478489]
[10]
Prabhu RS, Hwang J. Adjuvant therapy in biliary tract and gall bladder carcinomas: a review. Journal of gastrointestinal oncology. 2017 Apr:8(2):302-313. doi: 10.21037/jgo.2017.01.17. Epub
[PubMed PMID: 28480069]
[11]
Ben-Josef E, Guthrie KA, El-Khoueiry AB, Corless CL, Zalupski MM, Lowy AM, Thomas CR Jr, Alberts SR, Dawson LA, Micetich KC, Thomas MB, Siegel AB, Blanke CD. SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Aug 20:33(24):2617-22. doi: 10.1200/JCO.2014.60.2219. Epub 2015 May 11
[PubMed PMID: 25964250]
[12]
Benson AB 3rd, D'Angelica MI, Abbott DE, Abrams TA, Alberts SR, Saenz DA, Are C, Brown DB, Chang DT, Covey AM, Hawkins W, Iyer R, Jacob R, Karachristos A, Kelley RK, Kim R, Palta M, Park JO, Sahai V, Schefter T, Schmidt C, Sicklick JK, Singh G, Sohal D, Stein S, Tian GG, Vauthey JN, Venook AP, Zhu AX, Hoffmann KG, Darlow S. NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017. Journal of the National Comprehensive Cancer Network : JNCCN. 2017 May:15(5):563-573
[PubMed PMID: 28476736]
[13]
Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, Carter R, Tebbutt NC, Dervenis C, Smith D, Glimelius B, Charnley RM, Lacaine F, Scarfe AG, Middleton MR, Anthoney A, Ghaneh P, Halloran CM, Lerch MM, Oláh A, Rawcliffe CL, Verbeke CS, Campbell F, Büchler MW, European Study Group for Pancreatic Cancer. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA. 2012 Jul 11:308(2):147-56. doi: 10.1001/jama.2012.7352. Epub
[PubMed PMID: 22782416]
Level 1 (high-level) evidence
[14]
. Capecitabine Extends Survival for Biliary Tract Cancer. Cancer discovery. 2017 Jul:7(7):OF1. doi: 10.1158/2159-8290.CD-NB2017-079. Epub 2017 Jun 1
[PubMed PMID: 28572460]
[15]
Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J, ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. The New England journal of medicine. 2010 Apr 8:362(14):1273-81. doi: 10.1056/NEJMoa0908721. Epub
[PubMed PMID: 20375404]
[16]
Guro H, Kim JW, Choi Y, Cho JY, Yoon YS, Han HS. Multidisciplinary management of intrahepatic cholangiocarcinoma: Current approaches. Surgical oncology. 2017 Jun:26(2):146-152. doi: 10.1016/j.suronc.2017.03.001. Epub 2017 Mar 7
[PubMed PMID: 28577720]